Dura Pharmaceuticals, Inc. v. Broudo — Quick Summary

Dura Pharmaceuticals, Inc. v. Broudo

544 U.S. 336 (2005), Supreme Court of the United States

In Brief

Dura Pharmaceuticals v. Broudo is a foundational Supreme Court decision in federal securities litigation that clarifies what plaintiffs must allege and ultimately prove to establish loss causation in a Rule 10b-5 action.

Key Issue

Does alleging that one purchased a security at an artificially inflated price, without more, adequately plead the element of loss causation in a §10(b)/Rule 10b-5 action?

The Rule

Under §10(b) and Rule 10b-5, a private securities-fraud plaintiff must plead and prove loss causation—that the defendant's misrepresentation or omission proximately caused the plaintiff's economic loss. An allegation that the plaintiff purchased at an artificially inflated price, standing alone, is insufficient. The complaint must provide the defendant with some indication of the loss and the causal connection the plaintiff has in mind, typically by alleging that the truth became known to the market (through a corrective disclosure or leakage) and that this revelation caused a subsequent price decline that produced the loss. See 15 U.S.C. § 78u-4(b)(4).

Bottom Line

No. Merely alleging that the plaintiff purchased stock at an artificially inflated price does not plead loss causation. The plaintiff must allege that the misrepresentation proximately caused an economic loss by showing that the truth became known and that this revelation led to a price drop that injured the plaintiff. The Supreme Court reversed the Ninth Circuit and remanded.

Why It Matters

Dura is the leading case on loss causation in securities fraud. It rejects the Ninth Circuit's "inflated purchase price" approach and requires plaintiffs to connect their losses to the market's assimilation of the truth about the alleged fraud. Practically, Dura shapes how complaints are drafted (alleging corrective disclosures or leakage and subsequent price drops), how motions to dismiss are litigated, how class certification and damages models are constructed (event studies to isolate fraud-related declines), and how cases are tried (proving that the misrepresentation—not other confounding factors—caused the loss). For law students, Dura is essential for understanding the distinction between transaction causation (reliance) and loss causation (proximate cause of economic harm), the interplay between Rule 8, Rule 9(b), and the PSLRA, and the broader policy of preventing securities laws from becoming insurance against investment losses.

Master More Securities Law Cases with Briefly

Get AI-powered case briefs, practice questions, and study tools to excel in your law studies.